Advertisement


Related Videos

Leukemia

Hagop Kantarjian, MD, on Blinatumomab in Precursor B-Cell ALL

Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 379, “BLAST: A Confirmatory, Single-Arm, Phase II Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE) Antibody Construct, in Patients With Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia,” and abstract 3704, “An Evaluation of Molecular Response in a Phase II Open-Label, Multicenter Confirmatory Study in Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Receiving Treatment With the BiTE Antibody Construct Blinatumomab,” presented by Nicola Gökbuget, MD.

Leukemia

Hagop Kantarjian, MD, on CAR T Cells in Relapsed/Refractory ALL

Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 380, “T Cells Engineered with a Chimeric Antigen Receptor (CAR)-Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children With Relapsed, Refractory ALL,” presented by Stephan A. Grupp, MD, PhD; abstract 381, “Intent-to-Treat Results of a Phase I Trial of CD19 Chimeric Antigen Receptor Engineered T Cells Using a Consistent Treatment Regimen Reveals a 67% Complete Response Rate in Relapsed, Refractory Acute Lymphoblastic Leukemia,” presented by Daniel W. Lee III, MD; and abstract 382, “CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients With Relapsed, Refractory B-Cell ALL,” presented by Jae H. Park, MD.

Lymphoma

Laurie Sehn, MD, on Lenalidomide Plus Rituximab in Previously Untreated Mantle Cell Lymphoma

Laurie Sehn, MD, of the BC Cancer Agency, on abstract 625, “Sustained Remission With the Combination Biologic Doublet of Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma: A Multicenter Phase II Study Report,” presented by Jia Ruan, MD, PhD.

Lymphoma

Bertrand Coiffier, MD, PhD, on Radiotherapy Plus R-CHOP in Localized Diffuse Large B-Cell Lymphoma

Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 393, “R-CHOP With or Without Radiotherapy in Nonbulky Limited-Stage Diffuse Large B-Cell Lymphoma: Preliminary Results of the Prospective Randomized Phase III 02-03 Trial from the Lysa/Goelams Group,” presented by Thierry Lamy, MD, PhD.

Hematologic Malignancies

Keith McCrae, MD, on Caplacizumab in Thrombotic Thrombocytopenic Purpura

Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 229, “Caplacizumab, Anti-Vwf Nanobody Potentially Changing the Treatment Paradigm in Thrombotic Thrombocytopenic Purpura: Results of the TITAN Trial,” presented by Flora Peyvandi, MD.

Advertisement

Advertisement




Advertisement